Neurotrophic keratitis is a rare degenerative corneal disease caused by impaired corneal trigeminal innervation, resulting in reduced corneal sensitivity and poor epithelial healing that can progress to ulceration and perforation.
Krystal Biotech said IOLITE enrollment for KB803 is complete and it remains on track for KB803 and KB801 registrational data readouts in 2026. The company also reported FDA platform technology designations for KB407 and KB111 and continued VYJUVEK expansion.
Krystal Biotech is set to report fourth-quarter results with analysts expecting $1.58 a share on $106.16 million in revenue. Investors are watching Vyjuvek growth and pipeline programs including KB801, KB407 and KB707.
Krystal Biotech posted Q4 2025 net revenue of $107.1 million from Vyjuvek sales, with full-year revenue reaching $389.1 million. The company expanded to over 90 patients across Germany, France, and Japan while advancing its pipeline with new FDA designations.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07568730 |
A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis |
RECRUITING | PHASE2 |
| NCT07073729 |
Corneal Neurotization vs. Cenergermin for Neurotrophic Keratitis: A Pilot Study |
NOT_YET_RECRUITING | NA |
| NCT06999733 |
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis |
RECRUITING | PHASE1/PHASE2 |
| NCT06975748 |
A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis |
RECRUITING | PHASE2 |
| NCT06964269 |
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease |
RECRUITING | PHASE4 |
| NCT06947850 |
DOMPE -MT Neurotrophic Keratitis |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT06597422 |
A Study of STSP-0902 Ophthalmic Solution in Healthy Subjects |
COMPLETED | PHASE1 |
| NCT06411145 |
Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis |
WITHDRAWN | PHASE4 |
| NCT06364657 |
Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye |
TERMINATED | |
| NCT05927428 |
Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis |
RECRUITING | PHASE2 |
